Drug Profile
VX 880
Alternative Names: Allogeneic human stem cell-derived islet cell therapy - Vertex Pharmaceuticals; Stem cell-derived beta cells - Vertex Pharmaceuticals; Stem cell-derived fully differentiated pancreatic islet cell therapy - Vertex Pharmaceuticals; STx-02; VX-880Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Semma Therapeutics
- Developer Vertex Pharmaceuticals
- Class Cell therapies; Stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Type 1 diabetes mellitus
Most Recent Events
- 23 Apr 2024 Vertex Pharmaceuticals and TreeFrog Therapeutics enter into exclusive licensing agreement for TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes
- 03 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Type 1 diabetes mellitus presented at the 59th annual meeting of European Association for the Study of Diabetes (EASD-2023)
- 02 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Type 1 diabetes mellitus presented at the 59th annual meeting of European Association for the Study of Diabetes (EASD-2023)